Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue and NA-931 Phase 3 Launch
Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue from Bioxentra Life Sciences, Inc. and NA-931 Phase 3 Launch SAN JOSE, CA, UNITED STATES, May 5, 2026 /EINPresswire.com/ -- — Biomed Industries, Inc. …